ATE314856T1 - Ribozym-therapie zur behandlung von proliferativen augenkranheiten - Google Patents

Ribozym-therapie zur behandlung von proliferativen augenkranheiten

Info

Publication number
ATE314856T1
ATE314856T1 AT00975399T AT00975399T ATE314856T1 AT E314856 T1 ATE314856 T1 AT E314856T1 AT 00975399 T AT00975399 T AT 00975399T AT 00975399 T AT00975399 T AT 00975399T AT E314856 T1 ATE314856 T1 AT E314856T1
Authority
AT
Austria
Prior art keywords
eye diseases
treatment
proliferative
ribozyme therapy
proliferative eye
Prior art date
Application number
AT00975399T
Other languages
English (en)
Inventor
Joan M Robbins
Richard Tritz
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Application granted granted Critical
Publication of ATE314856T1 publication Critical patent/ATE314856T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
AT00975399T 1999-10-26 2000-10-26 Ribozym-therapie zur behandlung von proliferativen augenkranheiten ATE314856T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16153299P 1999-10-26 1999-10-26

Publications (1)

Publication Number Publication Date
ATE314856T1 true ATE314856T1 (de) 2006-02-15

Family

ID=22581562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00975399T ATE314856T1 (de) 1999-10-26 2000-10-26 Ribozym-therapie zur behandlung von proliferativen augenkranheiten

Country Status (7)

Country Link
EP (1) EP1223950B1 (de)
JP (1) JP2003530309A (de)
AT (1) ATE314856T1 (de)
AU (1) AU781151B2 (de)
CA (1) CA2388924A1 (de)
DE (1) DE60025391D1 (de)
WO (1) WO2001030362A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078390B1 (en) * 1999-10-15 2006-07-18 Gentier Biosystems Incorporation Ribozymes to growth factor originating in human platelet
DE10122206A1 (de) * 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
WO2004042061A1 (en) * 2002-11-08 2004-05-21 Klaus Strebhardt Pharmaceutical composition for suppressing undesired gene expression
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
ES2381201T3 (es) * 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
RU2011136531A (ru) * 2009-02-06 2013-03-20 Фрайе Универзитэт Берлин Фармацевтическая композиция для лечения побочных действий посредством приема шпигельмеров
US8877808B2 (en) 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
WO1995007924A1 (en) * 1993-09-17 1995-03-23 Andy Shih Ribozyme-based compositions for the modification of cutaneous phenotypes associated with aging and other conditions of the skin and hair
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
DE69619132T2 (de) * 1995-11-14 2002-07-18 Vimrx Holdings Ltd Chimäre oligomere mit einer rns-spaltungsaktivität
EP0902836A4 (de) * 1996-04-02 2004-12-22 Gene Shears Pty Ltd Asymmetrische hammerhead-ribozyme
US5990302A (en) * 1996-07-12 1999-11-23 Toyo Boseki Kabushiki Kaisha Method for isolating ribonucleic acid
JP2002506028A (ja) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 糖尿病性網膜症または眼炎症の処置におけるゲニステインのようなタンパク質チロシンインヒビターの使用
EP1086212A2 (de) * 1998-03-27 2001-03-28 Ribozyme Pharmaceuticals, Inc. Verfahren und wirkstoffe zur behandlung von krankheiten und zustände die mit angiogenese faktoren zusammenhängen
AU2476200A (en) * 1998-12-04 2000-06-19 Immusol, Inc Ribozyme therapy for the treatment and/or prevention of restenosis

Also Published As

Publication number Publication date
CA2388924A1 (en) 2001-05-03
JP2003530309A (ja) 2003-10-14
WO2001030362A2 (en) 2001-05-03
AU1345601A (en) 2001-05-08
WO2001030362A3 (en) 2002-01-17
EP1223950A2 (de) 2002-07-24
EP1223950B1 (de) 2006-01-04
DE60025391D1 (de) 2006-03-30
AU781151B2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
DK1425035T3 (da) Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling..
MXPA02001099A (es) Compuestos para modular el receptor rage.
ATE429922T1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
ATE313328T1 (de) Verfahren zur behandlung von mittelohrinfektionen
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE314856T1 (de) Ribozym-therapie zur behandlung von proliferativen augenkranheiten
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE486634T1 (de) Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
RS102304A (en) Composition for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
DK1343472T3 (da) Thixotropisk næsespray
WO2006031607A3 (en) A method of treating cancer
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60238395D1 (de) Ess-protein und verfahren zur verwendung davon
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE364625T1 (de) Proteine aus yaba monkey tumor virus mit modulatorischer aktivität
PT1267940E (pt) Compostos para direccionamento
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases
DE60023944D1 (de) Replikationsunfähige herpesvirus-vektoren
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
WO2024026308A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties